Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 4/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451476 | 0.88 | PGR (0.71) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL12054668 | 0.87 | KEAP1 (0.75) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL1488031 | 0.81 | KEAP1 (0.60) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL4175815 | 0.80 | HPGD (0.70) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL31041151 | 0.80 | KIF11 (0.79) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL82733 | 0.78 | CA1 (0.64) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL522309 | 0.78 | KEAP1 (0.62) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL1488032 | 0.78 | ALDH1A1 (0.68) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| Lithium SCHEMBL31041154 | 0.78 | KIF11 (0.76) | KEAP1ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL7988528 | 0.77 | HPGD (0.64) | ALDH1A1SMN1; SMN2LMNAHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114727983-A | Xanthine CB1 inhibitors | 金翅雀生物公司 | 2022-07-08 | — | — | CN | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2164833-A2 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009010139-A2 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | WO | claimed |
| CN-101331133-A | Sulphonamidoaniline derivatives as Janus kinase inhibitors | NOVARTIS AG (CH) | 2008-12-24 | — | — | CN | claimed |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | claimed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-6759428-B2 | SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS | ROCHE PALO ALTO LLC | 2004-07-06 | — | — | US | claimed |
| US-20040077646-A1 | Indole nitriles | ROCHE PALO ALTO LLC | 2004-04-22 | — | — | US | claimed |
| US-4975444-A | INHIBITORS OF ANGIORENSIN-CONVERTING ENZYME AS WELL AS A ENDOPEPTIDASE; CARDIOTONIC AGENTS; GLAUCOMA; DIURETICS | PFIZER INC. (US) | 1990-12-04 | — | — | US | claimed |
| CN-114727983-A | Xanthine CB1 inhibitors | 金翅雀生物公司 | 2022-07-08 | — | — | CN | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| CN-1088578-A | 3 (2H)-pyridazinone derivatives and preparation method thereof | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1994-06-29 | — | — | CN | disclosed |
| EP-0602521-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-06-22 | — | — | EP | disclosed |
| CN-1053429-A | INDOLE-SUBSTITUTED FIVE-MEMBERED HETEROAROMATIC COMPOUNDS | MERCK SHARP & DOHME (GB) | 1991-07-31 | — | — | CN | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077646-A1 | Indole nitriles | TPH1, IDO1, NAT1 | KEAP1 1751/4885ALDH1A1 535/4885SMN1; SMN2 1862/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | KEAP1 923/4885ALDH1A1 585/4885SMN1; SMN2 442/4885 |
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | KEAP1 3256/4885ALDH1A1 2994/4885SMN1; SMN2 3036/4885 |
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | KEAP1 880/4885ALDH1A1 1776/4885SMN1; SMN2 3148/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | KEAP1 923/4885ALDH1A1 585/4885SMN1; SMN2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.